Trial Profile

A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ecopipam (Primary)
Indications Gilles de la Tourette's syndrome
Focus Adverse reactions; Registrational
Sponsors Emalex Biosciences

Most Recent Events

28 Aug 2023 Status changed from planning to recruiting.
27 Apr 2023 Trial design presented at the 75th Annual Meeting of the American Academy of Neurology 2023
01 Mar 2023 According to an Emalex Biosciences media release, first patient was dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com